TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease.
McDonough
Clark
C
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Medical College of Georgia, 1120 15th Street, BBR 5513, Augusta, GA 30912, USA.
Blanchard
Amy R
AR
D000280:Administration, Inhalation; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage*; D015992:Body Mass Index; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D018450:Disease Progression; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D012307:Risk Factors; D000068299:Salmeterol Xinafoate; D012907:Smoking / Q000009:adverse effects; D013147:Spirometry; D016019:Survival Analysis
D000730:Androstadienes; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol